The Osteoarticular Manifestations in Patients With Gitelman Syndrome (NCT06922370) | Clinical Trial Compass
RecruitingNot Applicable
The Osteoarticular Manifestations in Patients With Gitelman Syndrome
China120 participantsStarted 2021-11-01
Plain-language summary
Patients with clinically and genetically confirmed Gitelman Syndrome are screened for CPPD, and the clinical and radiographic manifestations are collected and analyzed.
Who can participate
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients confirmed with Gitelman Syndrome
Exclusion Criteria:
* Patients with other confounding situations such as Bartter Syndrome, hyperparathyroidism
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is specifically looking at joint and bone problems in people with Gitelman syndrome, including something called chondrocalcinosis — can you explain what chondrocalcinosis is and whether I might already have signs of it that we should be looking for?
2Since Gitelman syndrome is relatively rare and this study seems focused on better understanding its effects on joints rather than testing a treatment, what would participating actually involve for me day-to-day, and would it require extra imaging or visits beyond my usual care?
3This trial is listed as Phase NA, which suggests it's an observational or natural history study rather than a drug trial — does that mean there's no experimental treatment involved, and could the data collected actually help guide my own future care?
4Given that Gitelman syndrome is already linked to low magnesium and potassium levels, how might those deficiencies connect to calcium pyrophosphate deposits in my joints, and is this something my current treatment plan is already addressing?
5Are there standard ways to screen for or manage joint complications like CPPD in Gitelman syndrome patients right now, or is that exactly the kind of gap this study is trying to fill — and would joining help ensure I get closer monitoring of my joints?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
The presence of chondrocalcinosis
Timeframe: From the enrollment to the performance of the CPPD screen
Trial details
NCT IDNCT06922370
SponsorSecond Affiliated Hospital, Zhejiang University, School of Medicine